Appetite-suppressing drugs could wipe out millions of fast-food trips. What it means for your choices and your money.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

McDonald’s stock was heading for its longest losing streak in 12 years after Redburn Atlantic recommended investors sell due ...

Here's why McDonald's is more exposed than other fast-food brands to shifts in eating habits as a result of weight-loss drugs ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, ...

The price of weight loss drugs is falling, making them more accessible to consumers, and the price could get driven even lower.Highly sought-after drugs like Wegovy and Zepbound both retail at roughly ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...